David Delaney - Net Worth and Insider Trading
David Delaney Net Worth
The estimated net worth of David Delaney is at least $74,515 dollars as of 2024-05-24. David Delaney is the of Pasithea Therapeutics Corp and owns about 11,376 shares of Pasithea Therapeutics Corp (KTTA) stock worth over $74,515. Details can be seen in David Delaney's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that David Delaney has not made any transactions after 2022-10-17 and currently still holds the listed stock(s).
Transaction Summary of David Delaney
David Delaney Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, David Delaney owns 1 companies in total, including Pasithea Therapeutics Corp (KTTA) .
Click here to see the complete history of David Delaney’s form 4 insider trades.
Insider Ownership Summary of David Delaney
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| KTTA | Pasithea Therapeutics Corp | 2022-10-17 | other: Member of 10% owner group |
David Delaney Latest Holdings Summary
David Delaney currently owns a total of 1 stock. David Delaney owns 11,376 shares of Pasithea Therapeutics Corp (KTTA) as of October 17, 2022, with a value of $74,515.
Latest Holdings of David Delaney
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| KTTA | Pasithea Therapeutics Corp | 2022-10-17 | 11,376 | 6.55 | 74,515 |
Holding Weightings of David Delaney
David Delaney Form 4 Trading Tracker
According to the SEC Form 4 filings, David Delaney has made a total of 1 transactions in Pasithea Therapeutics Corp (KTTA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Pasithea Therapeutics Corp is the acquisition of 50 shares on October 17, 2022, which cost David Delaney around $1,110.
Insider Trading History of David Delaney
- 1
David Delaney Trading Performance
GuruFocus tracks the stock performance after each of David Delaney's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by David Delaney is -35.12%. GuruFocus also compares David Delaney's trading performance to market benchmark return within the same time period. The performance of stocks bought by David Delaney within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how David Delaney's insider trading performs compared to the benchmark.
Performance of David Delaney
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -5.41 | | | | | |
| Relative Return to S&P 500(%) | -12.71 | | | | | |
David Delaney Ownership Network
David Delaney Owned Company Details
What does Pasithea Therapeutics Corp do?
Who are the key executives at Pasithea Therapeutics Corp?
David Delaney is the other: Member of 10% owner group of Pasithea Therapeutics Corp. Other key executives at Pasithea Therapeutics Corp include Chief Development Officer Graeme Martin Currie , 10 percent owner Paul B Manning , and 10 percent owner Bradford Manning .
Pasithea Therapeutics Corp (KTTA) Insider Trades Summary
Over the past 18 months, David Delaney made no insider transaction in Pasithea Therapeutics Corp (KTTA). Other recent insider transactions involving Pasithea Therapeutics Corp (KTTA) include a net purchase of 30,000 shares made by Lawrence Steinman ,
In summary, during the past 3 months, insiders sold 0 shares of Pasithea Therapeutics Corp (KTTA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pasithea Therapeutics Corp (KTTA) were sold and 1,500 shares were bought by its insiders, resulting in a net purchase of 1,500 shares.
Pasithea Therapeutics Corp (KTTA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Pasithea Therapeutics Corp Insider Transactions
David Delaney Mailing Address
Above is the net worth, insider trading, and ownership report for David Delaney. You might contact David Delaney via mailing address: C/o Concord Investment Partners Ltd., 60 St. Clair Avenue East, Suite 702, Toronto A6 M4t 1n5.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
